What do systematic reviews say?

Single‐dose intravesical chemotherapy instillation vs placebo or observation after nephroureterectomy

The review found no eligible studies for this question.

• Single‐dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Impact of extended vs standard lymph node dissection on overall survival among patients with urothelial cancer of the bladder

Impact of extended showed no clear difference in time to death from any cause (absolute effect size estimates based… compared with standard lymph node dissection on overall survival among patients… (low certainty).

• Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical… 2019 · Cochrane Headline outcomes only
  HR 0.78 [0.57, 1.07]
  1 study · 401 participants
  Low

Impact of extended vs standard lymph node dissection on overall survival among patients with urothelial cancer of the bladder

Impact of extended showed no clear difference in time to death from bladder cancer (absolute effect size estimates… compared with standard lymph node dissection on overall survival among patients… (low certainty).

• Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical… 2019 · Cochrane Headline outcomes only
  HR 0.7 [0.45, 1.07]
  1 study · 401 participants
  Low

Impact of extended vs standard lymph node dissection on overall survival among patients with urothelial cancer of the bladder

It is very uncertain whether impact of extended changes clavien‐Dindo grade ≥ 3 complications compared with standard lymph node dissection on overall survival among patients… (very low certainty).

• Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical… 2019 · Cochrane Headline outcomes only
  RR 1.13 [0.84, 1.52]
  1 study · 401 participants
  Very low

Impact of extended vs standard lymph node dissection on overall survival among patients with urothelial cancer of the bladder

It is very uncertain whether impact of extended changes time to recurrence (absolute effect size estimates based on… compared with standard lymph node dissection on overall survival among patients… (very low certainty).

• Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical… 2019 · Cochrane Headline outcomes only
  HR 0.84 [0.58, 1.22]
  1 study · 401 participants
  Very low

Impact of extended vs standard lymph node dissection on overall survival among patients with urothelial cancer of the bladder

It is very uncertain whether impact of extended changes clavien‐Dindo grade ≤ 2 complications8 compared with standard lymph node dissection on overall survival among patients… (very low certainty).

• Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical… 2019 · Cochrane Headline outcomes only
  RR 0.94 [0.74, 1.19]
  1 study · 401 participants
  Very low

Impact of extended vs standard lymph node dissection on overall survival among patients with urothelial cancer of the bladder

The review found no eligible studies for this question.

• Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Whole gland primary cryotherapy vs external beam radiotherapy (EBRT)

It is very uncertain whether whole gland primary cryotherapy changes time to death from prostate cancer (absolute effects:… compared with external beam radiotherapy (EBRT) (very low certainty).

• Primary cryotherapy for localised or locally advanced prostate cancer 2018 · Cochrane Headline outcomes only
  HR 1 [0.11, 9.45]
  2 studies · 293 participants
  Very low

Whole gland primary cryotherapy vs external beam radiotherapy (EBRT)

• Primary cryotherapy for localised or locally advanced prostate cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 195 participants
  Very low

Whole gland primary cryotherapy vs external beam radiotherapy (EBRT)

• Primary cryotherapy for localised or locally advanced prostate cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 195 participants
  Very low

Whole gland primary cryotherapy vs external beam radiotherapy (EBRT)

• Primary cryotherapy for localised or locally advanced prostate cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 195 participants
  Very low

Whole gland primary cryotherapy vs external beam radiotherapy (EBRT)

It is very uncertain whether whole gland primary cryotherapy changes major adverse events compared with external beam radiotherapy (EBRT) (very low certainty).

• Primary cryotherapy for localised or locally advanced prostate cancer 2018 · Cochrane Headline outcomes only
  RR 0.91 [0.47, 1.78]
  2 studies · 293 participants
  Very low

Whole gland primary cryotherapy vs external beam radiotherapy (EBRT)

It is very uncertain whether whole gland primary cryotherapy changes time to death from any cause (absolute effects: overall mortality) compared with external beam radiotherapy (EBRT) (very low certainty).

• Primary cryotherapy for localised or locally advanced prostate cancer 2018 · Cochrane Headline outcomes only
  HR 0.99 [0.05, 18.79]
  2 studies · 293 participants
  Very low

Whole gland primary cryotherapy vs external beam radiotherapy (EBRT)

The review found no eligible studies for this question.

• Primary cryotherapy for localised or locally advanced prostate cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Naftopidil vs tamsulosin

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  12 studies · 965 participants
  Moderate

Naftopidil vs silodosin (alpha‐blocker)

Naftopidil probably leads to lower sexual adverse events compared with silodosin (alpha‐blocker) (moderate certainty).

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 0.15 [0.06, 0.42]
  4 studies · 348 participants
  Moderate

Naftopidil vs propiverine (anticholinergic)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  Low

Naftopidil vs propiverine (anticholinergic)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  Low

Naftopidil vs propiverine (anticholinergic)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  GRADE not reported

Naftopidil vs propiverine (anticholinergic)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  GRADE not reported